"EnLyte-D provides all bioactive coenzyme & cofactors needed for optimal neurotransmitter synthesis, optimal antioxidant production, and optimal homocysteine reduction. The high prevalence of MTHFR and other inborn errors of metabolism (IEM’s) seen in neurological disease argue for treatment EnLyte-D."
Andrew Farah, MD, Chief of Psychiatry, UNC/HPRHS
INDICATED FOR THE CLINICAL DIETARY MANAGEMENT OF:
Major Depressive Disorder
Addiction and/or Abuse Abatement
Peripheral Neuropathic Pain/Tingling
Early and End-Stage Renal Disease
Age-Related Macular Degeneration
EnLyte-D is an FDA approved medical food to be used under medical supervision that has been speciﬁcally formulated for patients with methylenetetrahydrofolate reductase (MTHFR) genotypes and/or genotypes in Vitamin D transport and other B-Vitamin polymorphisms that may contribute to hyperhomocysteinemia and/or Vitamin D deﬁciency. EnLyte-D provides patients special, medically determined nutrient requirements including L-Methylfolate, Vitamin D, and other B vitamin coenzymes and mineral co-factors in amounts that cannot be achieved by the modiﬁcation of the normal diet alone.